SIGA Technologies, Inc. (SIGA)
| Market Cap | 389.16M |
| Revenue (ttm) | 110.78M |
| Net Income (ttm) | 33.90M |
| Shares Out | 72.20M |
| EPS (ttm) | 0.46 |
| PE Ratio | 11.72 |
| Forward PE | 8.55 |
| Dividend | $0.45 (8.35%) |
| Ex-Dividend Date | May 16, 2022 |
| Volume | 677,114 |
| Open | 5.60 |
| Previous Close | 5.53 |
| Day's Range | 5.38 - 5.68 |
| 52-Week Range | 5.11 - 26.99 |
| Beta | 0.87 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 4, 2023 |
About SIGA
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York. [Read more]
Full Company ProfileFinancial Performance
In 2022, SIGA's revenue was $110.78 million, a decrease of -17.13% compared to the previous year's $133.67 million. Earnings were $33.90 million, a decrease of -51.18%.
Financial StatementsNews
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2022
- Approximately $71 Million of International Product Sales in 2022 -
SIGA Technologies to Host Business Update Call on March 2nd, 2023 Following Release of Fourth Quarter and Full Year 2022 Financial Results
NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference...
SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023
SIGA Board of Directors has initiated search for new CEO; Dr. Gomez expected to remain in position as CEO until the search is completed to support the transition to a new CEO in 2023 SIGA Board of Dir...
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2022
- Approximately $61 Million of International Sales in the Third Quarter –
SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference...
SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on ...
SIGA Stock Alert: Siga Technologies Receives $11 Million Order for Monkeypox Drug
It's a great day to be invested in Siga Technologies (NASDAQ: SIGA) stock — or at least, it ought to be. The markets can be mysterious sometimes, though.
SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX®
- In 2022, the U.S. Department of Defense has Awarded Procurement Contracts for the Purchase of up to $18.1 Million of Oral TPOXX – - In 2022, the U.S. Department of Defense has Awarded Procurement Co...
SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat)
- Order for Approximately $10 Million Funded by the European Commission –
3 Picks That Could Be the Next Meme Stock Champion
For those unfamiliar with the term, a meme stock is a stock that has seen an increase in price due to attention on social media platforms like Reddit. In recent months, we've seen meme stocks like Gam...
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
Monkeypox stocks, our topic for today, have had a mostly mixed performance so far in 2022. It is likely, however, that they could benefit from the similar tailwinds enjoyed by companies, such as Pfize...
7 Short-Squeeze Stocks to Put on Your Must-Watch List
The beaten-down stock market has created an opportunity for contrarian investors in short-squeeze stocks. Essentially, bearish traders must borrow the underlying securities which they are pessimistic ...
These three stocks recorded gains of over 200% year-to-date
In a year where investing in stocks was more challenging than usual, finding winning stocks has been tough.
SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX®
- IV TPOXX is an Important Option for Those Unable to Swallow –
Siga Technologies Stock May Be a Runner Now, But It Still Is a Good Value
There's a lot going on with Siga Technologies (NASDAQ: SIGA) stock lately. First of all, Siga released its second-quarter 2022 financial results.
SIGA Says It Plans to Seek FDA Approval of Monkeypox Drug
The monkeypox outbreak has sent the drugmaker's stock up more than 200% this year, though its antiviral remains hard to access in the U.S.
SIGA to Seek FDA Approval of Monkeypox Drug When Data Is Available
The monkeypox outbreak has sent the drugmaker's stock up more than 200% this year, though the company's monkeypox antiviral remains hard to access in the U.S.
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2022
- Approximately $9 Million of Product Sales in the Second Quarter, including First Oral TPOXX® Sale to the U.S. Department of Defense and Approximately $5 Million of International Sales –
Monkeypox Stocks GOVX, VRAX, SIGA Rocket on Vaccine Shortage Fears
Monkeypox stocks are rallying amid worries about a shortage of vaccines for the illness in the U.S. Additionally, in recent days, New York state, New York City and San Francisco have issued emergency ...
Why Is SIGA Technologies (SIGA) Stock Plunging 23% Today?
Shares of SIGA Technologies (NASDAQ: SIGA) closed lower by more than 20% following the release of a Food and Drug Administration (FDA) update. That update stated that SIGA's TPOXX, or tecovirimat, an...
SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results
NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference...
SIGA Stock Gains Another 11% on Monkeypox Virus Concerns
SIGA Technologies (NASDAQ: SIGA) stock is seeing double-digit gains once again, as investors grow increasingly bullish on biotech firms with vaccines combating monkeypox. This enthusiasm started yest...
Monkeypox Stocks SIGA, GOVX, BVNRY, CHMX, EBS Soar on Global Health Emergency
Drugs and vaccines used against smallpox are seen as the first line of defense against the rising tide of monkeypox infections. The post Monkeypox Stocks SIGA, GOVX, BVNRY, CHMX, EBS Soar on Global He...
SIGA Stock Soars as WHO Declares Monkeypox Global Health Emergency
It's not every day that SIGA stock trends in the financial media, but today vaccine stocks are in focus due to the spread of monkeypox. The post SIGA Stock Soars as WHO Declares Monkeypox Global Healt...